Imperial College London psychedelic research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Imperial College London is listed with 5 registered studies counted here, in London, United Kingdom. By compound: 5 psilocybin. By registry status: 1 recruiting, 3 completed and 1 status not reported. By phase: 1 early phase 1, 2 phase 1, 1 phase 2 and 1 not reported. Reported start years run from 2019 (earliest) to 2025 (latest).
Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 5 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 5 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 1 | 20% |
| Completed | 3 | 60% |
| Status not reported | 1 | 20% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 1 | 20% |
| Phase 1 | 2 | 40% |
| Phase 2 | 1 | 20% |
| Not reported | 1 | 20% |
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| PsiloIMAGINE: A Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm | NCT06798636 | Recruiting | Early Phase 1 | 2025-10-01 | Psilocybin |
| PsilOCD: A Pharmacological-Challenge Feasibility Study | NCT06258031 | Completed | Phase 1 | 2022-10-28 | Psilocybin |
| Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of Action | NCT05548075 | Status not reported | Not reported | 2022-08-15 | Psilocybin |
| Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study | NCT04505189 | Completed | Phase 1 | 2021-05-28 | Psilocybin |
| Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms | NCT03429075 | Completed | Phase 2 | 2019-01-07 | Psilocybin |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.